1
|
Kitamura R, Enghauser L, Miyamoto R, Ichikawa T, Aiso T, Masuda Y, Kajihara D, Kakihara H, Nonaka K. Mechanistic model of minute virus of mice elution behavior in anion exchange chromatography purification. Biotechnol Prog 2024:e3516. [PMID: 39443823 DOI: 10.1002/btpr.3516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 08/20/2024] [Accepted: 10/09/2024] [Indexed: 10/25/2024]
Abstract
This study aimed to propose a methodology for developing a mechanistic model for viral clearance of the minute virus of mice (MVM) on flow-through anion exchange (AEX) chromatography. Protein surface analysis was applied to investigate the possibility of molecular interaction between the recombinant biotherapeutic and MVM. The protein product-free Tris buffers were spiked with MVM, and the MVM elution profile from AEX chromatography was quantitatively analyzed using quantitative polymerase chain reaction (qPCR) for pooled fractions. GoSilico™ Chromatography Modeling Software was applied to develop the mechanistic models for MVM species. For evaluating the visual fit of the developed model, the R2 of intact MVM virions and uncoated capsids between the simulated and measured amount in each fraction are 0.880 and 0.948, respectively. Response surface plots of logarithmic reduction values (LRV) against pH and conductivity in loaded sample were generated to show the range for suitable loaded sample conditions for achieving a good LRV. To evaluate the applicability of the developed MVM elution model to a recombinant biotherapeutic, two demonstrations of AEX chromatography purification were performed with a loaded sample of a model monoclonal antibody. The peaks of the MVM species in the elution step of both runs were accurately simulated by the developed model. In addition, to assess the possibility of molecular interaction between the virus and the target protein significantly affecting the MVM elution behavior, the antibody's surface was evaluated in terms of hydrophobicity/hydrophilicity using surface analysis.
Collapse
Affiliation(s)
- Ryunosuke Kitamura
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Lena Enghauser
- Cytiva, Global Life Sciences Solutions Germany GmbH, Karlsruhe, Germany
| | - Riku Miyamoto
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Takahiro Ichikawa
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Takaki Aiso
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Yumiko Masuda
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Daisuke Kajihara
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Hirofumi Kakihara
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| | - Koichi Nonaka
- Biologics Technology Research Laboratories I, Biologics Division, Daiichi Sankyo Co., Ltd., Akaiwa, Gunma, Japan
| |
Collapse
|
2
|
Sanchez-Martinez ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y. CHO cells for virus-like particle and subunit vaccine manufacturing. Vaccine 2024; 42:2530-2542. [PMID: 38503664 DOI: 10.1016/j.vaccine.2024.03.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 02/27/2024] [Accepted: 03/13/2024] [Indexed: 03/21/2024]
Abstract
Chinese Hamster Ovary (CHO) cells, employed primarily for manufacturing monoclonal antibodies and other recombinant protein (r-protein) therapeutics, are emerging as a promising host for vaccine antigen production. This is exemplified by the recently approved CHO cell-derived subunit vaccines (SUV) against respiratory syncytial virus (RSV) and varicella-zoster virus (VZV), as well as the enveloped virus-like particle (eVLP) vaccine against hepatitis B virus (HBV). Here, we summarize the design, production, and immunogenicity features of these vaccine and review the most recent progress of other CHO-derived vaccines in pre-clinical and clinical development. We also discuss the challenges associated with vaccine production in CHO cells, with a focus on ensuring viral clearance for eVLP products.
Collapse
Affiliation(s)
- Zalma V Sanchez-Martinez
- Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada
| | - Sergio P Alpuche-Lazcano
- Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada
| | - Matthew Stuible
- Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada; PROTEO: The Quebec Network for Research on Protein Function, Structure, and Engineering, Université du Québec à Montréal, 201 Avenue du Président Kennedy, Montréal, QC H2X 3Y7, Canada.
| |
Collapse
|
3
|
Krause S, Capito F, Oeinck V, Flato H, Hoffmann H, Ötes O, Berg A. Understanding virus retention mechanisms on protein a chromatography based on using different wash buffers - Evaluating the possibility for a generic wash buffer toolbox to improve virus clearance capacity. BIOTECHNOLOGY NOTES (AMSTERDAM, NETHERLANDS) 2024; 5:50-57. [PMID: 39416690 PMCID: PMC11446380 DOI: 10.1016/j.biotno.2024.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 03/18/2024] [Accepted: 03/20/2024] [Indexed: 10/19/2024]
Abstract
During manufacturing of mammalian-cell derived monoclonal antibodies (mAbs) virus clearance capacity of the downstream process has to be demonstrated. The protein A chromatography step typically achieves less than 4 log10 and is not considered as a major contributing step. Having been successfully applied to host cell protein removal before, we used different wash buffers for three mAbs with two model viruses (Minute virus of mice and Murine leukemia virus) in series as well as separately to further understand major contributing interactions for virus retention and potentially design a generic toolbox of stringent wash buffers to be applied to various mAbs. Results indicate a major relevance of hydrophobic interaction for Murine leukemia virus (xMuLV) and mAb A, based on improved clearance for buffers additionally containing increased levels of hydrophobic compounds. This effect was less pronounced for Minute virus of mice (MVM), whereby hydrogen-bonds were expected to play a stronger role for this model virus. Additionally, electrostatic interactions presumably are more relevant for MVM retention compared to xMuLV under the conditions evaluated. A generic mAb and virus-independent stringent wash buffer toolbox could not be identified. However, based on our results a customized mAb and virus wash buffer design with improved virus clearance is possible, with here demonstrated log reduction increase by 1.3 log10 for MVM and 2.2 log10 for xMuLV for the protein A step compared to equilibration buffer alone.
Collapse
Affiliation(s)
- Sandra Krause
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Development -Purification Development, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Florian Capito
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Development -Purification Development, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Verena Oeinck
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Development -Purification Development, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Hendrik Flato
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Development -Purification Development, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Holger Hoffmann
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Development -Purification Development, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Ozan Ötes
- Sanofi-Aventis Deutschland GmbH, R&D Microbial Platform Bioprocess Engineering, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| | - Annette Berg
- Sanofi-Aventis Deutschland GmbH, R&D Microbial Platform Bioprocess Engineering, Industriepark Höchst, 65926, Frankfurt am Main, Germany
| |
Collapse
|
4
|
Alpuche-Lazcano SP, Stuible M, Akache B, Tran A, Kelly J, Hrapovic S, Robotham A, Haqqani A, Star A, Renner TM, Blouin J, Maltais JS, Cass B, Cui K, Cho JY, Wang X, Zoubchenok D, Dudani R, Duque D, McCluskie MJ, Durocher Y. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells. COMMUNICATIONS MEDICINE 2023; 3:116. [PMID: 37612423 PMCID: PMC10447459 DOI: 10.1038/s43856-023-00340-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Accepted: 07/25/2023] [Indexed: 08/25/2023] Open
Abstract
BACKGROUND As the COVID-19 pandemic continues to evolve, novel vaccines need to be developed that are readily manufacturable and provide clinical efficacy against emerging SARS-CoV-2 variants. Virus-like particles (VLPs) presenting the spike antigen at their surface offer remarkable benefits over other vaccine antigen formats; however, current SARS-CoV-2 VLP vaccines candidates in clinical development suffer from challenges including low volumetric productivity, poor spike antigen density, expression platform-driven divergent protein glycosylation and complex upstream/downstream processing requirements. Despite their extensive use for therapeutic protein manufacturing and proven ability to produce enveloped VLPs, Chinese Hamster Ovary (CHO) cells are rarely used for the commercial production of VLP-based vaccines. METHODS Using CHO cells, we aimed to produce VLPs displaying the full-length SARS-CoV-2 spike. Affinity chromatography was used to capture VLPs released in the culture medium from engineered CHO cells expressing spike. The structure, protein content, and glycosylation of spikes in VLPs were characterized by several biochemical and biophysical methods. In vivo, the generation of neutralizing antibodies and protection against SARS-CoV-2 infection was tested in mouse and hamster models. RESULTS We demonstrate that spike overexpression in CHO cells is sufficient by itself to generate high VLP titers. These VLPs are evocative of the native virus but with at least three-fold higher spike density. In vivo, purified VLPs elicit strong humoral and cellular immunity at nanogram dose levels which grant protection against SARS-CoV-2 infection. CONCLUSIONS Our results show that CHO cells are amenable to efficient manufacturing of high titers of a potently immunogenic spike protein-based VLP vaccine antigen.
Collapse
Affiliation(s)
- Sergio P Alpuche-Lazcano
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Matthew Stuible
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Bassel Akache
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Anh Tran
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - John Kelly
- Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Dr, Ottawa, ON, K1A 0R6, Canada
| | - Sabahudin Hrapovic
- Aquatic and Crop Resources Development Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Anna Robotham
- Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Dr, Ottawa, ON, K1A 0R6, Canada
| | - Arsalan Haqqani
- Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Dr, Ottawa, ON, K1A 0R6, Canada
| | - Alexandra Star
- Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Dr, Ottawa, ON, K1A 0R6, Canada
| | - Tyler M Renner
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Julie Blouin
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Jean-Sébastien Maltais
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Brian Cass
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Kai Cui
- Nanotechnology Research Centre, National Research Council Canada, 11421 Saskatchewan Drive, Edmonton, AB, T6G 2M9, Canada
| | - Jae-Young Cho
- Nanotechnology Research Centre, National Research Council Canada, 11421 Saskatchewan Drive, Edmonton, AB, T6G 2M9, Canada
| | - Xinyu Wang
- Nanotechnology Research Centre, National Research Council Canada, 11421 Saskatchewan Drive, Edmonton, AB, T6G 2M9, Canada
| | - Daria Zoubchenok
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada
| | - Renu Dudani
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Diana Duque
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Michael J McCluskie
- Human Health Therapeutics Research Centre, National Research Council Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada.
| |
Collapse
|
5
|
A direct RT qPCR method for quantification of retrovirus-like particles in biopharmaceutical production with CHO cells. J Pharm Biomed Anal 2020; 189:113472. [PMID: 32693202 DOI: 10.1016/j.jpba.2020.113472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 07/09/2020] [Accepted: 07/10/2020] [Indexed: 11/22/2022]
Abstract
Chinese hamster ovary (CHO) cells are the host cell of choice for manufacturing biologic drugs, like monoclonal antibody, in the biopharmaceutical industry. Retrovirus-like particles (RVLPs) are made during the manufacturing process with CHO cells and it is incumbent upon the manufacturer to perform risk assessment based on levels of RVLP in unprocessed bulk. Quantification of RVLP using electron microscopy (EM) is the standard method. However, reverse transcription based real-time PCR (RT qPCR) is an alternative method available. This method involves RNase digestion of cell culture fluid to remove free RNA, followed by extraction of total nucleic acid and digestion with DNase to remove extracted DNA molecules, and then finally reverse transcription and PCR. Here we report a method where the nucleic acids extraction step is eliminated prior to qPCR. In this method the cell-free culture supernatant sample is digested with thermolabile DNase and RNase at the same time in a 96-well PCR plate; subsequently the enzymes are heat-denatured; then RT qPCR reagents are added to the wells in the PCR plate along with standards and controls in other wells of the same plate; finally the plate is subjected to RT qPCR for analysis of RVLP RNA in the samples. This direct RT qPCR method for RVLP is sensitive to 10 particles of RVLP with good precision and accuracy and has a wide linear range of quantification. The method has been successfully tested with different production batches, shown to be consistent, and correlates well with the extraction-based method. However, the results are about 1-log higher compared to EM method. This method simplifies the RVLP quantification protocol, reduces time of analysis and leads to increased assay sensitivity and development of automated high-throughput methods. Additionally, the method can be an added tool for viral clearance studies, by testing process-intermediate samples like Protein A column and ion-exchange column eluates, for increased confidence in purification of biologics manufactured in CHO cell culture.
Collapse
|
6
|
Masuda Y, Ogino Y, Yamaichi K, Takahashi Y, Nonaka K, Wakamatsu K. The prevention of an anomalous chromatographic behavior and the resulting successful removal of viruses from monoclonal antibody with an asymmetric charge distribution by using a membrane adsorber in highly efficient, anion-exchange chromatography in flow-through mode. Biotechnol Prog 2020; 36:e2955. [PMID: 31894893 DOI: 10.1002/btpr.2955] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 11/25/2019] [Accepted: 12/29/2019] [Indexed: 01/15/2023]
Abstract
Anion exchange (AEX) chromatography in the flow-through mode is a widely employed purification process for removal of process/product-related impurities and exogenous/endogenous viruses from monoclonal antibodies (mAbs). The pH of the mobile phase for AEX chromatography is typically set at half a unit below the isoelectric point (pI) of each mAb (i.e., pI - 0.5) or lower and, in combination with a low ionic strength, these conditions are usually satisfactory for both the recovery of the mAb and removal of impurities. However, we have recently encountered a tight binding of mAb1 to AEX resins under these standard chromatographic conditions. This anomalous adsorption behavior appears to be an effect of the asymmetric charge distribution on the surface of the mAb1. We found that mAb1 did not bind to the AEX resins if the mobile phase has a much lower pH and higher ionic strength, but those conditions would not allow adequate virus removal. We predicted that the use of membrane adsorbers might provide effective mAb1 purification, since the supporting matrix has a network structure that would be less susceptible to interactions with the asymmetric charge distribution on the protein surface. We tested the Natriflo HD-Q AEX membrane adsorber under standard chromatographic conditions and found that mAb1 flowed through the membrane adsorber, resulting in successful separation from murine leukemia virus. This AEX membrane adsorber is expected to be useful for process development because mAbs can be purified under similar standard chromatographic conditions regardless of their charge distributions.
Collapse
Affiliation(s)
- Yumiko Masuda
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd, Ohra-gun, Gunma, Japan.,Graduate School of Science and Technology, Gunma University, Kiryu-shi, Gunma, Japan
| | - Yuka Ogino
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd, Ohra-gun, Gunma, Japan
| | - Kozo Yamaichi
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd, Ohra-gun, Gunma, Japan
| | - Yusuke Takahashi
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd, Ohra-gun, Gunma, Japan
| | - Koichi Nonaka
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd, Ohra-gun, Gunma, Japan
| | - Kaori Wakamatsu
- Graduate School of Science and Technology, Gunma University, Kiryu-shi, Gunma, Japan
| |
Collapse
|
7
|
Duroy PO, Bosshard S, Schmid-Siegert E, Neuenschwander S, Arib G, Lemercier P, Masternak J, Roesch L, Buron F, Girod PA, Xenarios I, Mermod N. Characterization and mutagenesis of Chinese hamster ovary cells endogenous retroviruses to inactivate viral particle release. Biotechnol Bioeng 2019; 117:466-485. [PMID: 31631325 PMCID: PMC7003738 DOI: 10.1002/bit.27200] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/10/2019] [Accepted: 10/15/2019] [Indexed: 12/26/2022]
Abstract
The Chinese hamster ovary (CHO) cells used to produce biopharmaceutical proteins are known to contain type‐C endogenous retrovirus (ERV) sequences in their genome and to release retroviral‐like particles. Although evidence for their infectivity is missing, this has raised safety concerns. As the genomic origin of these particles remained unclear, we characterized type‐C ERV elements at the genome, transcriptome, and viral particle RNA levels. We identified 173 type‐C ERV sequences clustering into three functionally conserved groups. Transcripts from one type‐C ERV group were full‐length, with intact open reading frames, and cognate viral genome RNA was loaded into retroviral‐like particles, suggesting that this ERV group may produce functional viruses. CRISPR‐Cas9 genome editing was used to disrupt the gag gene of the expressed type‐C ERV group. Comparison of CRISPR‐derived mutations at the DNA and RNA level led to the identification of a single ERV as the main source of the release of RNA‐loaded viral particles. Clones bearing a Gag loss‐of‐function mutation in this ERV showed a reduction of RNA‐containing viral particle release down to detection limits, without compromising cell growth or therapeutic protein production. Overall, our study provides a strategy to mitigate potential viral particle contaminations resulting from ERVs during biopharmaceutical manufacturing.
Collapse
Affiliation(s)
- Pierre-Olivier Duroy
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.,Present address: Selexis SA, Plan-les-Ouates, Switzerland
| | - Sandra Bosshard
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.,Present address: Lonza AG, Visp, Switzerland
| | | | | | | | - Philippe Lemercier
- Swiss-Prot Group, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland
| | - Jacqueline Masternak
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland
| | - Lucien Roesch
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland
| | - Flavien Buron
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland
| | | | - Ioannis Xenarios
- Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.,Present address: Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Nicolas Mermod
- Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
8
|
Namila FNU, Zhang D, Traylor S, Nguyen T, Singh N, Wickramasinghe R, Qian X. The effects of buffer condition on the fouling behavior of MVM virus filtration of an Fc‐fusion protein. Biotechnol Bioeng 2019; 116:2621-2631. [DOI: 10.1002/bit.27085] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 05/21/2019] [Accepted: 06/06/2019] [Indexed: 11/09/2022]
Affiliation(s)
- FNU Namila
- Department of Biomedical Engineering University of Arkansas Fayetteville Arkansas
| | - Da Zhang
- Department of Chemical Engineering University of Arkansas Fayetteville Arkansas
| | | | | | | | | | - Xianghong Qian
- Department of Biomedical Engineering University of Arkansas Fayetteville Arkansas
| |
Collapse
|
9
|
Masuda Y, Tsuda M, Hashikawa-Muto C, Takahashi Y, Nonaka K, Wakamatsu K. Cation exchange chromatography performed in overloaded mode is effective in removing viruses during the manufacturing of monoclonal antibodies. Biotechnol Prog 2019; 35:e2858. [PMID: 31148380 DOI: 10.1002/btpr.2858] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 04/29/2019] [Accepted: 05/29/2019] [Indexed: 11/07/2022]
Abstract
Viral safety is a critical concern with regard to monoclonal antibody (mAb) products produced in mammalian cells such as Chinese hamster ovary cells. Manufacturers are required to ensure the safety of such products by validating the clearance of viruses in downstream purification steps. Cation exchange (CEX) chromatography is widely used in bind/elute mode as a polishing step in mAb purification. However, bind/elute modes require a large volume of expensive resin. To reduce the production cost, the use of CEX chromatography in overloaded mode has recently been investigated. The viral clearance ability in overloaded mode was evaluated using murine leukemia virus (MLV). Even under high-load conditions such as 2,000 g mAb/L resin, MLV was removed from mAb solutions. This viral clearance ability was not significantly affected by resin type or mAb type. The overloaded mode can also remove other types of viruses such as pseudorabies virus and reovirus Type 3 from mAb solutions. Based on these results, this cost-effective overloaded mode is comparable to the bind-elute mode in terms of viral removal.
Collapse
Affiliation(s)
- Yumiko Masuda
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Ohra-gun, Gunma, Japan.,Graduate School of Science and Technology, Gunma University, Kiryu-shi, Gunma, Japan
| | - Masashi Tsuda
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Ohra-gun, Gunma, Japan
| | - Chie Hashikawa-Muto
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Ohra-gun, Gunma, Japan
| | - Yusuke Takahashi
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Ohra-gun, Gunma, Japan
| | - Koichi Nonaka
- Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Ohra-gun, Gunma, Japan
| | - Kaori Wakamatsu
- Graduate School of Science and Technology, Gunma University, Kiryu-shi, Gunma, Japan
| |
Collapse
|
10
|
Li S, Cha SW, Heffner K, Hizal DB, Bowen MA, Chaerkady R, Cole RN, Tejwani V, Kaushik P, Henry M, Meleady P, Sharfstein ST, Betenbaugh MJ, Bafna V, Lewis NE. Proteogenomic Annotation of Chinese Hamsters Reveals Extensive Novel Translation Events and Endogenous Retroviral Elements. J Proteome Res 2019; 18:2433-2445. [PMID: 31020842 DOI: 10.1021/acs.jproteome.8b00935] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A high-quality genome annotation greatly facilitates successful cell line engineering. Standard draft genome annotation pipelines are based largely on de novo gene prediction, homology, and RNA-Seq data. However, draft annotations can suffer from incorrect predictions of translated sequence, inaccurate splice isoforms, and missing genes. Here, we generated a draft annotation for the newly assembled Chinese hamster genome and used RNA-Seq, proteomics, and Ribo-Seq to experimentally annotate the genome. We identified 3529 new proteins compared to the hamster RefSeq protein annotation and 2256 novel translational events (e.g., alternative splices, mutations, and novel splices). Finally, we used this pipeline to identify the source of translated retroviruses contaminating recombinant products from Chinese hamster ovary (CHO) cell lines, including 119 type-C retroviruses, thus enabling future efforts to eliminate retroviruses to reduce the costs incurred with retroviral particle clearance. In summary, the improved annotation provides a more accurate resource for CHO cell line engineering, by facilitating the interpretation of omics data, defining of cellular pathways, and engineering of complex phenotypes.
Collapse
Affiliation(s)
| | | | | | - Deniz Baycin Hizal
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | - Raghothama Chaerkady
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | | | - Vijay Tejwani
- Colleges of Nanoscale Science and Engineering , SUNY Polytechnic Institute , Albany , New York 12203 , United States
| | - Prashant Kaushik
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Michael Henry
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Paula Meleady
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Susan T Sharfstein
- Colleges of Nanoscale Science and Engineering , SUNY Polytechnic Institute , Albany , New York 12203 , United States
| | | | | | | |
Collapse
|
11
|
Cetlin D, Pallansch M, Fulton C, Vyas E, Shah A, Sohka T, Dhar A, Pallansch L, Strauss D. Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration. Biotechnol Prog 2018; 34:1213-1220. [DOI: 10.1002/btpr.2694] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 06/08/2018] [Accepted: 07/18/2018] [Indexed: 11/11/2022]
Affiliation(s)
- David Cetlin
- MockV Solutions, Inc. RD 22, Baltimore Road Rockville Maryland, 20850
| | | | - Coral Fulton
- Texcell N.A. 4991 New Design Road Frederick Maryland, 21703
| | - Esha Vyas
- Asahi Kasei America Inc 1855, Elmdale Avenue, Glenview Illinois, 60026
| | - Aesha Shah
- Asahi Kasei America Inc 1855, Elmdale Avenue, Glenview Illinois, 60026
| | - Taka Sohka
- Asahi Kasei America Inc 1855, Elmdale Avenue, Glenview Illinois, 60026
| | - Arun Dhar
- Animal and Comparative Biomedial SciencesAquaculture Pathology Lab University of Arizona 1117 E Lowell Street, VSM Building, Room 201, Tucson Arizona, 85721
| | - Luke Pallansch
- Texcell N.A. 4991 New Design Road Frederick Maryland, 21703
| | - Daniel Strauss
- Asahi Kasei America Inc 1855, Elmdale Avenue, Glenview Illinois, 60026
| |
Collapse
|
12
|
Rupp O, MacDonald ML, Li S, Dhiman H, Polson S, Griep S, Heffner K, Hernandez I, Brinkrolf K, Jadhav V, Samoudi M, Hao H, Kingham B, Goesmann A, Betenbaugh MJ, Lewis NE, Borth N, Lee KH. A reference genome of the Chinese hamster based on a hybrid assembly strategy. Biotechnol Bioeng 2018; 115:2087-2100. [PMID: 29704459 PMCID: PMC6045439 DOI: 10.1002/bit.26722] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 03/13/2018] [Accepted: 04/25/2018] [Indexed: 12/20/2022]
Abstract
Accurate and complete genome sequences are essential in biotechnology to facilitate genome‐based cell engineering efforts. The current genome assemblies for Cricetulus griseus, the Chinese hamster, are fragmented and replete with gap sequences and misassemblies, consistent with most short‐read‐based assemblies. Here, we completely resequenced C. griseus using single molecule real time sequencing and merged this with Illumina‐based assemblies. This generated a more contiguous and complete genome assembly than either technology alone, reducing the number of scaffolds by >28‐fold, with 90% of the sequence in the 122 longest scaffolds. Most genes are now found in single scaffolds, including up‐ and downstream regulatory elements, enabling improved study of noncoding regions. With >95% of the gap sequence filled, important Chinese hamster ovary cell mutations have been detected in draft assembly gaps. This new assembly will be an invaluable resource for continued basic and pharmaceutical research.
Collapse
Affiliation(s)
- Oliver Rupp
- Bioinformatics and Systems Biology, Justus-Liebig-University Giessen, Giessen, Germany
| | - Madolyn L MacDonald
- Department of Computer and Information Sciences, University of Delaware, Newark, Delaware.,Delaware Biotechnology Institute, Newark, Delaware
| | - Shangzhong Li
- Department of Bioengineering, University of California, San Diego, California.,Novo Nordisk Foundation Center for Biosustainability, University of California, San Diego, California
| | - Heena Dhiman
- Austrian Center of Industrial Biotechnology, Vienna, Austria.,Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Shawn Polson
- Department of Computer and Information Sciences, University of Delaware, Newark, Delaware.,Delaware Biotechnology Institute, Newark, Delaware
| | - Sven Griep
- Bioinformatics and Systems Biology, Justus-Liebig-University Giessen, Giessen, Germany
| | - Kelley Heffner
- Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland
| | - Inmaculada Hernandez
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Karina Brinkrolf
- Department of Biorescources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany
| | - Vaibhav Jadhav
- Austrian Center of Industrial Biotechnology, Vienna, Austria
| | - Mojtaba Samoudi
- Novo Nordisk Foundation Center for Biosustainability, University of California, San Diego, California.,Department of Pediatrics, University of California, San Diego, California
| | - Haiping Hao
- Johns Hopkins University Deep Sequencing and Microarray Core, Johns Hopkins University, Baltimore, Maryland
| | | | - Alexander Goesmann
- Bioinformatics and Systems Biology, Justus-Liebig-University Giessen, Giessen, Germany
| | - Michael J Betenbaugh
- Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland
| | - Nathan E Lewis
- Department of Bioengineering, University of California, San Diego, California.,Novo Nordisk Foundation Center for Biosustainability, University of California, San Diego, California.,Department of Pediatrics, University of California, San Diego, California
| | - Nicole Borth
- Austrian Center of Industrial Biotechnology, Vienna, Austria.,Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Kelvin H Lee
- Delaware Biotechnology Institute, Newark, Delaware.,Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware
| |
Collapse
|
13
|
Chinniah S, Hinckley P, Connell-Crowley L. Characterization of operating parameters for XMuLV inactivation by low pH treatment. Biotechnol Prog 2015; 32:89-97. [DOI: 10.1002/btpr.2183] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 10/05/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Shivanthi Chinniah
- Cellular Resources, Amgen Inc, One Amgen Center Drive; Thousand Oaks CA 91320
| | - Peter Hinckley
- Drug Substance Development, Amgen Inc; 1201 Amgen Court West Seattle WA 98119
| | | |
Collapse
|
14
|
Anwaruzzaman M, Wang W, Wang E, Erfe L, Lee J, Liu S. Evaluation of infectivity and reverse transcriptase real-time polymerase chain reaction assays for detection of xenotropic murine leukemia virus used in virus clearance validation. Biologicals 2015; 43:256-65. [PMID: 25997567 DOI: 10.1016/j.biologicals.2015.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 01/17/2015] [Accepted: 04/05/2015] [Indexed: 11/18/2022] Open
Abstract
Infectivity and reverse transcriptase quantitative real-time polymerase chain reaction (qRT-PCR) assays have been optimized and validated for xenotropic murine leukemia virus (X-MuLV) detection. We have evaluated the assays systematically with regard to specificity, linearity, lower limit of detection (LLOD), lower limit of quantification (LLOQ), and precision. Both assays are specific for X-MuLV detection, with a linear detection range of 0.6-5.6 log(10) TCID(50)/mL for the infectivity assay, and 1.4-6.5 log(10) particles/mL for the qRT-PCR assay. The LLOD and LLOQ of the infectivity and the qRT-PCR assays are determined as 0.5 and 1.0 log(10)/mL, and 1.4 and 2.2 log(10)/mL. The inter-assay repeatability of qRT-PCR assay (4.2% coefficient of variation [CV]) is higher than the infectivity assay (7.9% CV). We have shown that both assays are closely correlated (r = 0.85, P < 0.05, n = 22). The particle/infectivity ratio is determined as 66. Both assays were applied to evaluate virus removal using virus clearance samples of chromatographic and filtration processes. Here, we have demonstrated that the qRT-PCR assay is much faster in testing and is approximately 8-fold more sensitive than the infectivity assay. Therefore, the qRT-PCR assay can replace the infectivity assay in many cases, but both assays are complementary in elucidating the mechanism of virus inactivation and removal in virus clearance validation.
Collapse
Affiliation(s)
- Mohammad Anwaruzzaman
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA
| | - Wensheng Wang
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA
| | - Eunice Wang
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA
| | - Lolita Erfe
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA
| | - Janice Lee
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA
| | - Shengjiang Liu
- Pathogen Safety Department, Global Biologics Development, Bayer HealthCare Pharmaceuticals, Berkeley, CA, USA.
| |
Collapse
|
15
|
Bach J, Connell-Crowley L. Clearance of the rodent retrovirus, XMuLV, by protein A chromatography. Biotechnol Bioeng 2015; 112:743-50. [PMID: 25335906 DOI: 10.1002/bit.25484] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Revised: 10/06/2014] [Accepted: 10/15/2014] [Indexed: 01/15/2023]
Affiliation(s)
- Julia Bach
- Drug Substance Development; Amgen Inc.; 1201 Amgen Court West; Seattle 98119 Washington
| | - Lisa Connell-Crowley
- Drug Substance Development; Amgen Inc.; 1201 Amgen Court West; Seattle 98119 Washington
| |
Collapse
|
16
|
Matrix and backstage: cellular substrates for viral vaccines. Viruses 2014; 6:1672-700. [PMID: 24732259 PMCID: PMC4014716 DOI: 10.3390/v6041672] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 03/28/2014] [Accepted: 04/02/2014] [Indexed: 01/04/2023] Open
Abstract
Vaccines are complex products that are manufactured in highly dynamic processes. Cellular substrates are one critical component that can have an enormous impact on reactogenicity of the final preparation, level of attenuation of a live virus, yield of infectious units or antigens, and cost per vaccine dose. Such parameters contribute to feasibility and affordability of vaccine programs both in industrialized countries and developing regions. This review summarizes the diversity of cellular substrates for propagation of viral vaccines from primary tissue explants and embryonated chicken eggs to designed continuous cell lines of human and avian origin.
Collapse
|
17
|
Connell-Crowley L, Larimore EA, Gillespie R. Using high throughput screening to define virus clearance by chromatography resins. Biotechnol Bioeng 2013; 110:1984-94. [DOI: 10.1002/bit.24869] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2012] [Revised: 01/10/2013] [Accepted: 02/05/2013] [Indexed: 11/10/2022]
|
18
|
Mueller M, Wan C, Hoi KM, Kim DY, Gan HT, Bardor M, Gagnon P. Immunoglobulins M Survive Low-pH Conditions Used for Virus Inactivation and for Elution from Bioaffinity Columns. J Pharm Sci 2013; 102:1125-32. [DOI: 10.1002/jps.23428] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2012] [Revised: 11/20/2012] [Accepted: 11/30/2012] [Indexed: 11/08/2022]
|
19
|
Connell-Crowley L, Nguyen T, Bach J, Chinniah S, Bashiri H, Gillespie R, Moscariello J, Hinckley P, Dehghani H, Vunnum S, Vedantham G. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes. Biotechnol Bioeng 2011; 109:157-65. [DOI: 10.1002/bit.23300] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Revised: 07/11/2011] [Accepted: 07/28/2011] [Indexed: 11/07/2022]
|
20
|
Strauss DM, Cano T, Cai N, Delucchi H, Plancarte M, Coleman D, Blank GS, Chen Q, Yang B. Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production. Biotechnol Prog 2010; 26:750-5. [DOI: 10.1002/btpr.385] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Miesegaes G, Lute S, Brorson K. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 2010; 106:238-46. [DOI: 10.1002/bit.22662] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
22
|
Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 2009; 104:371-80. [DOI: 10.1002/bit.22416] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
23
|
Strauss DM, Lute S, Brorson K, Blank GS, Chen Q, Yang B. Removal of endogenous retrovirus-like particles from CHO-cell derived products using Q sepharose fast flow chromatography. Biotechnol Prog 2009; 25:1194-7. [DOI: 10.1002/btpr.249] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
24
|
Zhang M, Lute S, Norling L, Hong C, Safta A, O'Connor D, Bernstein LJ, Wang H, Blank G, Brorson K, Chen Q. A Novel, Q-PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography. Biotechnol Bioeng 2009; 102:1438-47. [DOI: 10.1002/bit.22172] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Strauss DM, Gorrell J, Plancarte M, Blank GS, Chen Q, Yang B. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products. Biotechnol Bioeng 2009; 102:168-75. [DOI: 10.1002/bit.22051] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
Detection and cloning of LINE-1 elements in CHO cells. Cytotechnology 2007; 53:75-80. [PMID: 19003192 DOI: 10.1007/s10616-007-9051-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2006] [Accepted: 01/25/2007] [Indexed: 10/23/2022] Open
Abstract
Long interspersed elements (LINEs, L1s) are non-long terminal repeat (LTR) retrotransposons found in mammalian genomes and account up to 20% of genomic DNA. It has been shown that active L1 elements can cause mutation resulting in disease, genetic variation and polymorphisms and their inactive copies seem to be involved in recombination and rearrangement. L1-encoded products have been detected in a number of tissues including mammalian germ cell tumours, breast carcinomas and a large variety of transformed mouse and human cell lines.Chinese Hamster Ovary (CHO) cells are widely used in the manufacture of recombinant proteins for biopharmaceuticals. Here, we investigated the transcriptional activity of hamster L1 elements in CHO-K1 cells. These cells were analysed for the presence of L1 RNA transcripts. The sequence, which is homologous to mammalian L1 elements, was cloned from hamster genomic DNA and used to design primers for RT-PCR. L1 transcripts were detected in CHO-K1 RNA.
Collapse
|
27
|
Fan XY, Lü GZ, Wu LN, Chen JH, Xu WQ, Zhao CN, Guo SQ. A modified single-tube one-step product-enhanced reverse transcriptase (mSTOS-PERT) assay with heparin as DNA polymerase inhibitor for specific detection of RTase activity. J Clin Virol 2006; 37:305-12. [PMID: 16971176 DOI: 10.1016/j.jcv.2006.08.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2006] [Revised: 07/03/2006] [Accepted: 08/09/2006] [Indexed: 10/24/2022]
Abstract
BACKGROUND Current regulations and recommendations proposed for the production of vaccines in continuous cell lines of any origin demand that these be free of exogenous viruses, particularly retroviruses. Recently, the ultra-sensitive product-enhanced reverse transcriptase (PERT) assay can be used to detect minute of reverse transcriptase (RTase) in single retroviral particle and is 10(6) times more sensitive than the conventional RTase assays. However, coincidental with this increase in sensitivity is an increase in false-positive reactions derived from contaminating cellular DNA polymerases, which are known to have RTase-like activities. OBJECTIVES To develop a modified single-tube one-step PERT (mSTOS-PERT) assay with improvements on decreasing significantly the level of false-positive reactions, and to evaluate the mSTOS-PERT assay for sensitivity and specificity. STUDY DESIGN Ampliwaxtrade mark was used to compartmentalize the reverse transcription (RT) and PCR step in the same micro-tube with more efficiency and reproducibility, while maintaining the high sensitivity. The DNA amplification products were separated by 2% agarose gel electrophoresis, and then analyzed by non-isotopic Southern blot hybridization. A wide variety of cell lines used in biologicals production were detected to validate the improved mSTOS-PERT assay. RESULTS The detection limit for the mSTOS-PERT assay was at least 10(-9)U, when using AMV-RTase as a positive control. Furthermore, heparin involvement in the RT step can eliminate completely the false-positive PERT signals which are exhibited by cellular polymerases such as DNA-dependent DNA polymerase alpha, gamma released by cell death. Most mammalian cells (MRC-5, Vero, WISH, 2BS, RK-13, MDCK, etc.) are PERT-negative in cell supernatants. Some PERT-positive signals in cell lysates were found to be introduced by the cellular DNA polymerases and could be inhibited specifically by heparin. Chick cells derived from either chick embryo fibroblasts (CEF) or allantoic fluid from SPF embryonated eggs, murine hybridoma cell SP2/0, etc., contained authentic RTase activities, which could not be inactivated by heparin. CONCLUSIONS The improved mSTOS-PERT assay described here may distinguish the genuine RTase activity from cellular polymerases with high sensitivity and specificity, and is rapid and easy to perform to screen for the possible contamination of minute retroviruses in the cell substrates used in vaccine production.
Collapse
Affiliation(s)
- Xiao-Yong Fan
- Department of Microbiology, School of Life Sciences, Fudan University, Shanghai 200433, China.
| | | | | | | | | | | | | |
Collapse
|
28
|
Shi L, Chen Q, Norling LA, Lau ASL, Krejci S, Xu Y. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. Biotechnol Bioeng 2005; 87:884-96. [PMID: 15334415 DOI: 10.1002/bit.20198] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Chinese hamster ovary cells used for pharmaceutical protein production express noninfectious retrovirus-like particles. To assure the safety of pharmaceutical proteins, validation of the ability of manufacturing processes to clear retrovirus-like particles is required for product registration. Xenotropic murine leukemia virus (X-MuLV) is often used as a model virus for clearance studies. Traditionally, cell-based infectivity assay has been the standard virus quantification method. In this article, a real time quantitative PCR (Q-PCR) method has been developed for X-MuLV detection/quantification. This method provides accurate and reproducible quantification of X-MuLV particle RNA (pRNA) over a linear dynamic range of at least 100,000-fold with a quantification limit of approximately 1.5 pRNA copies microL(-1). It is about 100-fold more sensitive than the cell-based infectivity assay. High concentrations of protein and cellular DNA present in test samples have been demonstrated to have no impact on X-MuLV quantification. The X-MuLV clearance during chromatography and filtration procedures determined by this method is highly comparable with that determined by the cell-based infectivity assay. X-MuLV clearance measured by both methods showed that anion exchange chromatography (QSFF) and DV50 viral filtration are robust retroviral removal steps. In addition, combination of the two methods was able to distinguish the viral removal from inactivation by the Protein A chromatography, and fully recognize the viral clearance capacity of this step. This new method offers significant advantages over cell-based infectivity assays. It could be used to substitute cell-based infectivity assays for process validation of viral removal procedures, but not inactivation steps. Its availability should greatly facilitate and reduce the cost of viral clearance evaluations for new biologic product development.
Collapse
Affiliation(s)
- Liming Shi
- Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA
| | | | | | | | | | | |
Collapse
|
29
|
Valera CR, Chen JW, Xu Y. Application of multivirus spike approach for viral clearance evaluation. Biotechnol Bioeng 2003; 84:714-22. [PMID: 14595784 DOI: 10.1002/bit.10825] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Viral contamination is a common risk to continuous cell line-derived biologics. Viral validation is thus required for license applications. Viral validation for chromatography procedures is routinely performed by spiking a model virus into the load material and performing the chromatography procedures at small scale under conditions equivalent to the commercial scale. With traditional cell-based infectivity assays, one can only spike one model virus at one time. Quantitative PCR methods (TaqMan) make it possible to spike multiple model viruses for a chromatography procedure simultaneously. TaqMan assays can quantify multiple types of viruses and other types of nucleic acid in a single sample without cross interference because of its extremely high specificity. Therefore, a multivirus spike approach was evaluated and compared to a single virus spike approach. The study was further extended to the evaluation of host cell DNA clearance. The data shows highly comparable viral and host cell DNA clearance between the single and multiple virus spike approaches. Application of a multivirus spike approach provides significant time, manpower, and cost savings for new drug development.
Collapse
|
30
|
Wurm FM, Jordan M. Gene transfer and gene amplification in mammalian cells. GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS 2003. [DOI: 10.1016/s0167-7306(03)38019-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
31
|
Wisher M. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther 2002; 9:1056-61. [PMID: 12522444 DOI: 10.1038/sj.cgt.7700536] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2002] [Indexed: 11/09/2022]
Abstract
Replication competent oncolytic viruses, like other biological products, are at risk from contamination by bacteria, fungi, mycoplasma and viruses that must be eliminated from the final product. This article reviews the regulatory guidance for the manufacture and testing for oncolytic virus products. A testing strategy covering the testing of cell lines, virus banks, virus harvests and purified product is described.
Collapse
|
32
|
Brorson K, De Wit C, Hamilton E, Mustafa M, Swann PG, Kiss R, Taticek R, Polastri G, Stein KE, Xu Y. Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol Bioeng 2002; 80:257-67. [PMID: 12226857 DOI: 10.1002/bit.10366] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cell culture process changes (e.g., changes in scale, medium formulation, operational conditions) and cell line changes are common during the development life cycle of a therapeutic protein. To ensure that the impact of such process changes on product quality and safety is minimal, it is standard practice to compare critical product quality and safety attributes before and after the changes. One potential concern introduced by cell culture process improvements is the possibility of increased endogenous retrovirus expression to a level above the clearance capability of the subsequent purification process. To address this, retrovirus expression was measured in scaled down and full production scaled Chinese hamster ovary (CHO) cell cultures of four monoclonal antibodies and one recombinant protein before and after process changes. Two highly sensitive, quantitative (Q)-PCR-based assays were used to measure endogenous retroviruses. It is shown that cell culture process changes that primarily alter media components, nutrient feed volume, seed density, cell bank source (i.e., master cell bank vs. working cell bank), and vial size, or culture scale, singly or in combination, do not impact the rate of retrovirus expression to an extent greater than the variability of the Q-PCR assays (0.2-0.5 log(10)). Cell culture changes that significantly alter the metabolic state of the cells and/or rates of protein expression (e.g., pH and temperature shifts, NaButyrate addition) measurably impact the rate of retrovirus synthesis (up to 2 log(10)). The greatest degree of variation in endogenous retrovirus expression was observed between individual cell lines (up to 3 log(10)). These data support the practice of measuring endogenous retrovirus output for each new cell line introduced into manufacturing or after process changes that significantly increase product-specific productivity or alter the metabolic state, but suggest that reassessment of retrovirus expression after other process changes may be unnecessary.
Collapse
Affiliation(s)
- Kurt Brorson
- Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Brorson K, Xu Y, Swann PG, Hamilton E, Mustafa M, de Wit C, Norling LA, Stein KE. Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. Biologicals 2002; 30:15-26. [PMID: 11846426 DOI: 10.1006/biol.2001.0290] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Murine hybridoma cells used in the production of monoclonal antibodies (mAbs) produce endogenous type C retrovirus particles. Regulatory agencies require a demonstration that mAbs intended for human use are free of retrovirus with an adequate margin of safety. This is usually achieved by evaluation studies, performed at small scale, to demonstrate that the manufacturing process is capable of removing or inactivating several different model viruses, including a murine retrovirus. In a previous report, we demonstrated the utility of TaqMan fluorogenic 5'-nuclease product-enhanced reverse transcriptase (TM-PERT) assays for measuring reverse transcriptase (RT) activity in laboratory-scale cell-culture samples and RT removal by laboratory-scale models of processing steps. In this report, we evaluate the specificity, accuracy, range, precision and robustness of TM-PERT for this purpose. We find that this assay detects RT activity contained in xenotropic murine leukemia virus (X-MuLV) and CHO cell type C particles and quantifies particle numbers comparably to other assays (e.g. transmission electron microscopy, viral sequence specific TaqMan). Cell derived DNA polymerases appear to contribute only modestly to the assay background and RT activity in clarified cell culture harvests is contained largely in Type C particles. TM-PERT is linear and precise between 10(7)and 10(13) pU/ml, establishing the assay range. The assay is robust in that test article storage condition and DNA/protein content had little impact on assay performance. Thus, TM-PERT appears to be an acceptable assay to measure type C particles in rodent cell culture samples.
Collapse
Affiliation(s)
- Kurt Brorson
- Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Charlebois TS, O'connell BD, Adamson SR, Brink-Nilsson H, Jernberg M, Eriksson B, Kelley BD. Viral safety of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38:32-9. [PMID: 11449333 DOI: 10.1016/s0037-1963(01)90106-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The possible transmission of blood-borne pathogens has been the impetus behind the development of recombinant products formulated in the absence of human-derived components. The viral safety of Chinese hamster ovary (CHO)-cell-based pharmaceuticals is well established. Over 100 million infusions have been administered without a single known incident of CHO-related viral transmission. The manufacturing process for B-domain deleted recombinant factor VIII (BDDrFVIII) builds on this safety record by using a state-of-the-art multitiered approach to viral safety. This approach includes: (1) extensive testing of the CHO cells used to produce BDDrFVIII; (2) routine viral monitoring of the cell culture production process; (3) a purification process in which a specific viral inactivation procedure has been included; (4) a final formulation that does not incorporate human albumin as the stabilizer; and (5) a thorough validation of the viral inactivation and removal capacity of the purification process. This multifaceted viral safety program offers the hemophilia community a factor VIII product with an exceptional degree of viral safety.
Collapse
|
35
|
de Wit C, Fautz C, Xu Y. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 2000; 28:137-48. [PMID: 10964440 DOI: 10.1006/biol.2000.0250] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Chinese hamster ovary (CHO) cells have been widely used to manufacture recombinant proteins intended for human therapeutic uses. Retrovirus-like particles, which are apparently defective and non-infectious, have been detected in all CHO cells by electron microscopy (EM). To assure viral safety of CHO cell-derived biologicals, quantification of retrovirus-like particles in production cell culture and demonstration of sufficient elimination of such retrovirus-like particles by the down-stream purification process are required for product market registration worldwide. EM, with a detection limit of 1x10(6) particles/ml, is the standard retrovirus-like particle quantification method. The whole process, which requires a large amount of sample (3-6 litres), is labour intensive, time consuming, expensive, and subject to significant assay variability. In this paper, a novel real-time quantitative PCR assay (TaqMan assay) has been developed for the quantification of retrovirus-like particles. Each retrovirus particle contains two copies of the viral genomic particle RNA (pRNA) molecule. Therefore, quantification of retrovirus particles can be achieved by quantifying the pRNA copy number, i.e. every two copies of retroviral pRNA is equivalent to one retrovirus-like particle. The TaqMan assay takes advantage of the 5'-->3' exonuclease activity of Taq DNA polymerase and utilizes the PRISM 7700 Sequence Detection System of PE Applied Biosystems (Foster City, CA, U.S.A.) for automated pRNA quantification through a dual-labelled fluorogenic probe. The TaqMan quantification technique is highly comparable to the EM analysis. In addition, it offers significant advantages over the EM analysis, such as a higher sensitivity of less than 600 particles/ml, greater accuracy and reliability, higher sample throughput, more flexibility and lower cost. Therefore, the TaqMan assay should be used as a substitute for EM analysis for retrovirus-like particle quantification in CHO cell-based production system.
Collapse
Affiliation(s)
- C de Wit
- Department of Cell Culture and Fermentation R&D, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | |
Collapse
|
36
|
Lovatt A, Black J, Galbraith D, Doherty I, Moran MW, Shepherd AJ, Griffen A, Bailey A, Wilson N, Smith KT. High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods 1999; 82:185-200. [PMID: 10894635 DOI: 10.1016/s0166-0934(99)00111-1] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The development and application of a novel, sensitive TaqMan fluorescent probe-based product enhanced RT test (F-PERT) for the detection of retrovirus are described. The assay allows discrimination between the amplification signals generated by genuine positive signals that result from retroviral RT activity and the RT-like activity from DNA polymerases. The RT-like activity from DNA polymerases was suppressed by the addition of activated calf-thymus DNA with no reduction in the RT activity. A linear relationship between threshold cycle (C(T)) and the number of virus particles was demonstrated, allowing quantification of retroviruses in unknown samples. The F-PERT assay was able to detect a wide range of retroviral RT activities, including that from porcine endogenous retrovirus (PoERV), murine leukaemia virus (MLV), simian foamy virus (SFV), simian immunodeficiency virus (SIVmac) and squirrel monkey retrovirus (SMRV). The detection limit of SMRV, MLV and PoERV was approximately 100 virion particles and the test was able to detect at least 10(2) molecules of purified RT enzyme. RT activity was not detected in cellular lysates and supernatants from MRC-5, BT, VERO, or Raji cells, whereas RT activity was detected in C1271, Mus dunni, K-Balb, BHK-21, CHO-K1, SP2/0-Ag14 and NSO cell supernatants. RT activity was also detected in the Spodoptera cell line Sf9.
Collapse
|
37
|
Wurm FM, Johnson A, Ryll T, Köhne C, Scherthan H, Glaab F, Lie YS, Petropoulos CJ, Arathoon WR. Gene transfer and amplification in CHO cells. Efficient methods for maximizing specific productivity and assessment of genetic consequences. Ann N Y Acad Sci 1996; 782:70-8. [PMID: 8659926 DOI: 10.1111/j.1749-6632.1996.tb40548.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- F M Wurm
- Genentech Inc., Process Sciences, South San Francisco, California 94080, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lie YS, Penuel EM, Low MA, Nguyen TP, Mangahas JO, Anderson KP, Petropoulos CJ. Chinese hamster ovary cells contain transcriptionally active full-length type C proviruses. J Virol 1994; 68:7840-9. [PMID: 7966574 PMCID: PMC237246 DOI: 10.1128/jvi.68.12.7840-7849.1994] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
We have isolated a genomic locus from Chinese hamster ovary (CHO) cells that contains a full-length provirus. Nucleotide sequence analysis indicates that it is a defective member of the rodent type C retrovirus family with an env region that is similar to those of mouse amphotropic retrovirus and subgroup B feline leukemia virus. We were able to demonstrate that this provirus is a member of a closely related family of full-length proviruses in CHO cells and Chinese hamster liver. Hybridization probes generated from this genomic clone were used to characterize type C retrovirus RNA expression in CHO cells. Full-length genomic RNA and subgenomic envelope mRNA were detected in CHO cell lines but not in the human-derived 293 cell line. Interestingly, we discovered that the site of retrovirus integration lies within a G repeat sequence belonging to the short interspersed element family of retroposons.
Collapse
Affiliation(s)
- Y S Lie
- Molecular Virology Laboratory, Genentech, Inc., South San Francisco, California 94080
| | | | | | | | | | | | | |
Collapse
|
39
|
Rein A, Harvin DP, Mirro J, Ernst SM, Gorelick RJ. Evidence that a central domain of nucleocapsid protein is required for RNA packaging in murine leukemia virus. J Virol 1994; 68:6124-9. [PMID: 8057495 PMCID: PMC237026 DOI: 10.1128/jvi.68.9.6124-6129.1994] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
We have analyzed RNA packaging by a series of mutants altered in the nucleocapsid (NC) protein of Moloney murine leukemia virus (Mo-MuLV). We found that mutants lacking residues 8 through 11 or 44 through 60 of NC package Mo-MuLV RNA with virtually the same efficiency as wild-type Mo-MuLV. In contrast, point mutants altered at the conserved cysteines in the cysteine array (residues 26 and 29) and a mutant lacking residues 16 through 23 packaged Mo-MuLV RNA with approximately 1% of the efficiency of wild-type Mo-MuLV. The deficiency in packaged RNA was observed not only in Northern (RNA) analysis but also in an RNA-PCR assay, which would detect degraded as well as intact RNA. One of the cysteine array mutants was also shown to be defective with respect to encapsidation of hygromycin phosphotransferase mRNA containing a Mo-MuLV packaging signal. We suggest that a central region of NC, consisting of the cysteine array and flanking basic residues, is required for RNA packaging in Mo-MuLV.
Collapse
Affiliation(s)
- A Rein
- ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702
| | | | | | | | | |
Collapse
|
40
|
Minor PD. Ensuring safety and consistency in cell culture production processes: viral screening and inactivation. Trends Biotechnol 1994; 12:257-61. [PMID: 7765074 DOI: 10.1016/0167-7799(94)90136-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The history of the use of biological products is littered with examples of the iatrogenic transmission of viruses. A major effort of the biotechnology industry is directed towards the elimination of any risk of infection from the products of cell culture. This article summarizes the overall strategy that has been followed, so far with great success, in that there have, as yet, been no reported cases of viral transmission by the products of biotechnology.
Collapse
Affiliation(s)
- P D Minor
- National Institute for Biological Standards and Control, Potters Bar, Herts., UK
| |
Collapse
|
41
|
|
42
|
Miller DG, Miller AD. Tunicamycin treatment of CHO cells abrogates multiple blocks to retrovirus infection, one of which is due to a secreted inhibitor. J Virol 1992; 66:78-84. [PMID: 1370096 PMCID: PMC238262 DOI: 10.1128/jvi.66.1.78-84.1992] [Citation(s) in RCA: 91] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Chinese hamster ovary (CHO) cells are resistant to infection by all of the major classes of murine retroviruses and are partially resistant to infection by gibbon ape leukemia virus. Treatment of CHO cells with the glycosylation inhibitor tunicamycin rendered these cells susceptible to infection by retroviral vectors with ecotropic, xenotropic, and amphotropic host ranges and increased the titer of gibbon ape leukemia virus pseudotyped vectors 10-fold. Vectors having a polytropic host range did not infect CHO cells in the presence or absence of tunicamycin, showing that the effect of tunicamycin was specific and related to the pseudotype of the vector. We present evidence for three mechanisms of resistance to infection: lack of viral receptors on CHO cells, the presence of nonfunctional receptors which can be made functional by treatment with tunicamycin, and the secretion of a protein factor that blocks retroviral infection of CHO cells. Several criteria indicate that the secreted inhibitor is not an interferon, and secretion of this factor was not detected in several other cell lines that were examined.
Collapse
Affiliation(s)
- D G Miller
- Fred Hutchinson Cancer Research Center, Seattle, Washington 98104
| | | |
Collapse
|
43
|
Abstract
Based on morphological, virological, biochemical and molecular biological data, it is proposed that the presence of endogenous retrovirus particles in the placental cytotrophoblasts of many mammals is indicative of some beneficial action provided by the virus in relation to cell fusion, syncytiotrophoblast formation and the creation of the placenta. Further, it is hypothesised that the germ line retroviral infection of some primitive mammal-like species resulted in the evolution of the placental mammals.
Collapse
Affiliation(s)
- J R Harris
- Institute of Cell and Tumour Biology, German Cancer Research Center, Heidelberg
| |
Collapse
|